X4 Pharmaceuticals, Inc

X4 Pharmaceuticals is dedicated to developing and commercializing innovative therapies for rare diseases of the immune system. They successfully developed mavorixafor, marketed as XOLREMDI®, and are advancing it for additional patient populations. Currently, they are enrolling participants in a pivotal Phase 3 clinical trial for chronic neutropenic disorders. Headquartered in Boston, X4 is publicly traded on the Nasdaq under the symbol XFOR.